Arrowhead’s Alzheimer’s disease drug reduces tau in Phase I/IIa trial
Arrowhead Pharmaceuticals’ investigational RNA interference (RNAi) therapy being developed for Alzheimer’s disease has been shown to reduce tau in a…
Latest News
-
-
BioNTech misses PFS endpoints in Phase II/III cancer vaccine trial
One of BioNTech's prospective cancer vaccines has failed to show benefit in one of its dual primary endpoints in a…
-
BMS gains two pivotal trial wins in lung disease and rare cancer
Bristol Myers Squibb (BMS) has seen success in two pivotal trials, one in idiopathic pulmonary fibrosis (IPF) and one in…
-
Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact
California-based biopharma company Alumis has debuted data from a trio of Phase III studies that the company says highlights the…
-
EU clinical trial advice pilot becomes permanent
The European Medicines Agency (EMA) is permanently putting its Accelerating Clinical Trials in the EU (ACT EU) pilot into practice.…
-
BMS’s Zenbexus meets PFS endpoint in pivotal multiple myeloma trial
Bristol Myers Squibb’s (BMS’s) Phase III trial of Zenbexus (iberdomide) has more than doubled progression-free survival (PFS) in patients with…
-
ArriVent’s stock plummets on Phase III NSCLC trial failure
ArriVent BioPharma’s stock has dropped 46% after a Phase III trial of its non-small cell lung cancer (NSCLC) candidate failed…
-
Cerevance’s novel Parkinson’s drug nets a Phase III win
Boston-based biotech Cerevance’s first-in-class Parkinson’s therapy, solengepras, has demonstrated its potential to improve both motor and non-motor symptoms in a…
-
Vaxcyte’s stock up after pneumococcal vaccine proves non-inferiority
Vaxcyte’s stock has skyrocketed as its invasive pneumococcal disease (IPD) and pneumococcal pneumonia vaccine has met its endpoints in a…
-
EADV26: Key late-stage readouts from the conference
In recent years, there has been an explosion in the range of therapies for immunological diseases, with the treatment paradigm…
